A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part V

Speciality: Oncology


Speaker:

Dr. Jessicca Lin | Attending Physician, Center for Thoracic Cancers & Henri and Belinda Termeer center for Targeted Therapies

Dr. T. Raja | Director of Medical Oncology, Senior Consultant in BMT Apollo Hospital

Dr. Amit Rauthan | Consultant in Medical Oncology, Hemato-Oncology & Transplant Manipal Hospital

Dr. B. K. Smruti | Consultant Medical Oncologist, Hemato-Oncologist, Bombay Hospital Institute of Medical Science

Description:

A warm welcome to all the medical professionals in this interesting learning session on first line management of ALK positive lung cancer.

In this webinar, a panel discussion would take place involving Dr. Jessicca Lin as the primary speaker and Dr. T. Raja, Dr. Amit Rauthan, Dr. B. K. Smruti and many other panelists who will share the important facts associated with first line management of ALK positive lung cancer.

Starting with the case scenario of non-small cell lung cancer, Dr Jessica has explained all details associated with the incidence, progression and treatment of ALK positive lung cancer. Further, the panel discussion will give more knowledge.

ALK-positive lung cancer represents about 4% of lung cancer which generally appears in adenocarcinoma non-small cell lung cancer. Patients with ALK-positive are mostly younger than the average lung cancer patient and also do not have a smoking history compared to other lung cancers.

Therefore,  you are going to have an overall knowledge regarding management of ALK positive lung cancer. Listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.


See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Lung cancer screening adherence rates decline annually after baseline screening

2.

MRI-guided radiation therapy improves quality of life with fewer side effects in patients with localized cancer. JAMA

3.

Weight-Based and Fixed-Dose Pembrolizumab Compared in NSCLC

4.

World's premier cancer institute faces crippling cuts and chaos

5.

Zebrafish models offer fast, effective guidance for personalized therapies for kids with high-risk cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot